Drug Approval | October 30, 2025
Granules India’s facility secures FDA EIR with 'VAI’
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated
